Drug profile · INN
cobimetinib fumarate
COTELLIC
cobimetinib fumarate (COTELLIC) is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — cobimetinib fumarate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
cobimetinib fumarate (COTELLIC) is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
Primary target: Dual specificity mitogen-activated protein kinase kinase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cobimetinib fumarate?
cobimetinib fumarate (COTELLIC) is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for cobimetinib fumarate?
COTELLIC is a marketed brand name for cobimetinib fumarate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cobimetinib fumarate?
cobimetinib fumarate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.